Please provide your email address to receive an email when new articles are posted on . The FDA has approved a supplemental new drug application that updates the indication statement for upadacitinib ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the GLP-1 receptor agonist dulaglutide for the reduction of major adverse cardiovascular events ...
Increased length of stay and cost of hospitalization in patients receiving inpatient radiation therapy. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...
Bloodstream infections present many challenges to clinicians. The number of hospitalized patients with blood-stream infection continues to increase, and the number of newly available antimicrobial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results